This shareable PDF can be hosted on any platform or network and is fully compliant with publisher copyright.
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
This page is a summary of: Long-Term Follow-Up of the Gem2010 Trial of Bortezomib-Melphalan-Prednisone and Lenalidomide-Dexamethasone in Elderly, Newly Diagnosed Multiple Myeloma Patients: Impact of Age, High-Risk Cytogenetics and Minimal Residual Disease, SSRN Electronic Journal, January 2018, Elsevier,
DOI: 10.2139/ssrn.3220103.
You can read the full text:
The following have contributed to this page
